Invention Publication
- Patent Title: INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
-
Application No.: US18509453Application Date: 2023-11-15
-
Publication No.: US20240294911A1Publication Date: 2024-09-05
- Inventor: James Butler , Kevin Fitzgerald , Gregory Hinkle , Brian Bettencourt , Huilei Xu
- Applicant: Alnylam Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- The original application number of the division: US15743349 2018.01.10
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61P5/06
Abstract:
The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
Information query
IPC分类:
